Studies how nerve signals affect blood pressure in adults with obesity
Tests whether vitamin C infusion changes nerve-driven blood vessel response in adults with obesity.
Key facts
- Who runs it
- University of Kansas Medical Center
- Where
- Kansas City, United StatesSee the site
- Trial code
- Registry title
- Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 Aug 2022
- Expected to end
- 1 Sept 2027
- Type of study
- Observational
- Treatments tested
- ascorbic acid
- Record updated
- 3 October 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for middle-aged adults with obesity and insulin resistance, without high blood pressure. It tests how a vitamin C drip changes the blood pressure response to nerve signals.
- Age
- 35-65 years in the inclusion criteria (the registry header lists 18 Years to 79 Years).
- Sex
- All sexes can join.
- Disease stage
- Obesity (BMI >25 m/kg2) with raised insulin resistance (HOMA-IR > 2.5), without high blood pressure.
- Earlier treatment
- People must be willing to stop vitamin C or E supplements and omega-3 fatty acids 2 weeks before. People taking a statin or blood pressure medicine cannot join.
- Biomarker or test result
- HOMA-IR > 2.5, calculated from fasting glucose and insulin in the blood.
Main reasons for not taking part
- Taking a statin or blood pressure medicine
- Blood pressure above 130/80 mmHg
- History of heart disease (for example heart attack, stent)
- History of vascular disease (for example bypass, stroke)
- Narrow angle glaucoma
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Obese: BMI >25 m/kg2
- Elevated insulin resistance: HOMA-IR > 2.5 (calculation based on fasting glucose and insulin concentrations in blood)
- Middle-aged: 35-65 years
- Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior
- Able and willing to provide written informed consent
Who cannot take part
- Currently taking a statin or antihypertension medication
- Hypertension: >130/80 mmHg
- History of heart disease (e.g., myocardial infarction, stent)
- History of vascular disease (e.g., bypass, stroke)
- Hyperlipidemia: Fasting triglycerides < 250 mg/dL
- Individuals with narrow angle glaucoma; -
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Where in United States
- University of Kansas Medical CenterKansas City, United StatesContact: Seth HolwerdaTaking people
About the trial
What the trial wants to find out
In addition to chronically elevated MSNA, there is a growing recognition that hypertension in states of insulin resistance and obesity may also be attributed to an increased vascular sensitivity to MSNA (1, 2, 13, 36-38). To study this phenomenon, we quantify vascular sensitivity to MSNA using an innovative, moment-to-moment assessment of the blood pressure response following individual bursts of muscle sympathetic nerve activity (MSNA), (10, 11, 34, 37). This approach is termed 'sympathetic-vascular transduction (SVT).' We will examine the hypothesis that SVT is exaggerated in obesity and insulin resistance and is attenuated by suppression of oxidative stress. Oxidative stress is the overabundance of reactive oxygen species and is another hallmark of hypertension, obesity, and insulin resistance. Oxidative stress can be safely reduced via intravenous infusion of ascorbic acid (Vit C) (4, 28). Therefore, we will use a randomized, double-blinded, placebo-controlled approach to test the hypothesis that elevated SVT will be attenuated by suppression of oxidative stress via ascorbic acid I.V. infusion compared with saline I.V. infusion (placebo) in obese adults with insulin resistance. Our study will identify a unique mechanism that can be targeted to reduce the excessively high prevalence of hypertension and risk for CVD in obesity and insulin resistance.
The group in the trial
- Obese
Treatment: ascorbic acid
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Concomitantly Higher Resting Arterial Blood Pressure and Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension
- Plain-language title
- Studies how nerve signals affect blood pressure in adults with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06626113, who can take part
- Record updated
- 3 October 2024